Literature DB >> 8349686

A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule.

K S Aulak1, E Eldering, C E Hack, Y P Lubbers, R A Harrison, A Mast, M Cicardi, A E Davis.   

Abstract

C1-inhibitor(Mo), a dysfunctional C1-inhibitor molecule produced in two kindred with type II hereditary angioedema, has a mutation at the P10 position (Ala436 to Thr). Like most serpins with hinge region mutations (P14, P12, P10), C1-inhibitor(Mo) loses its inhibitory activity. However, unlike the other hinge region mutations, this mutant is not converted to a substrate. As shown by nondenaturing gel electrophoresis, gel filtration, sucrose density gradient ultracentrifugation, and electron microscopy, C1-inhibitor(Mo) exists in both monomeric and multimeric forms. Polymerization probably results from reactive center loop insertion into the A sheet of an adjacent molecule. Native C1-inhibitor(Mo) was shown to have a thermal stability profile intermediate to those of intact and of cleaved normal C1-inhibitor. Native C1-inhibitor(Mo) did not bind to monoclonal antibody KII, which binds only to reactive center-cleaved normal C1-inhibitor. It did, however, react with monoclonal antibody KOK12, which recognizes complexed or cleaved C1-inhibitor but not intact normal C1-inhibitor. Native C1-inhibitor(Mo), therefore, exists in a conformation similar to the complexed form of normal C1-inhibitor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349686

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Protein fiber linear dichroism for structure determination and kinetics in a low-volume, low-wavelength couette flow cell.

Authors:  Timothy R Dafforn; Jacindra Rajendra; David J Halsall; Louise C Serpell; Alison Rodger
Journal:  Biophys J       Date:  2004-01       Impact factor: 4.033

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

3.  Serpin alpha 1proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy.

Authors:  H Koloczek; A Banbula; G S Salvesen; J Potempa
Journal:  Protein Sci       Date:  1996-11       Impact factor: 6.725

4.  Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp)

Authors:  D Bruce; D J Perry; J Y Borg; R W Carrell; M R Wardell
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

5.  Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis.

Authors:  R Mahadeva; W S Chang; T R Dafforn; D J Oakley; R C Foreman; J Calvin; D G Wight; D A Lomas
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 6.  Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders.

Authors:  David H Perlmutter; Gary A Silverman
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

Review 7.  Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology.

Authors:  D A Lomas; H Parfrey
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

8.  Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates.

Authors:  Meera Mallya; Russell L Phillips; S Adrian Saldanha; Bibek Gooptu; Sarah C Leigh Brown; Daniel J Termine; Arash M Shirvani; Ying Wu; Richard N Sifers; Ruben Abagyan; David A Lomas
Journal:  J Med Chem       Date:  2007-10-05       Impact factor: 7.446

9.  Probing the local conformational change of alpha1-antitrypsin.

Authors:  Je-Hyun Baek; Hana Im; Un-Beom Kang; Ki Moon Seong; Cheolju Lee; Joon Kim; Myeong-Hee Yu
Journal:  Protein Sci       Date:  2007-07-27       Impact factor: 6.725

10.  Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha1-antitrypsin: implications for disease and drug design.

Authors:  Bibek Gooptu; Elena Miranda; Irene Nobeli; Meera Mallya; Andrew Purkiss; Sarah C Leigh Brown; Charlotte Summers; Russell L Phillips; David A Lomas; Tracey E Barrett
Journal:  J Mol Biol       Date:  2009-02-14       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.